Close Menu

Aalto Bio Reagents Yellow Fever Monoclonal Antibodies

Jan 31, 2017

Aalto Bio Reagents announced the availability of its yellow fever monoclonal antibodies for diagnostic test manufacturers, vaccine developers, and researchers globally. The monoclonal antibodies are raised against cell-culture derived viral lysate from strain 17D. The yellow fever antibodies complement the firm's portfolio of recombinant proteins and antibodies for chikungunya, dengue, and Zika virus diagnostic tests.

More Like This

Jun 25, 2019

Co-Diagnostics Zika, Dengue, Chikungunya Multiplex Test

Co-Diagnostics announced the launch of its Logix Smart ZDC multiplex test at the 64th Annual 2019 Caribbean Public Health Agency Health Research Conference in Trinidad and Tobago.

The firm designed the ZDC multiplex test to detect the presence of Zika, dengue, and chikungunya within a single polymerase chain reaction assay. The firm said that the performance of the test confirms the heightened specificity provided by its CoPrimer platform in multiplex PCR applications. Co-Diagnostics received CE marking for the ZDC multiplex test in the first quarter after validating its performance, permitting its marketing throughout the European Community, Latin America, the Caribbean Basin, and other jurisdictions that accept the CE designation.

Jun 24, 2019

Agilent NovoCyte Advanteon Flow Cytometer

Agilent Technologies launched the NovoCyte Advanteon Flow Cytometer. It is the first product from Agilent's recently acquired ACEA Biosciences. the NovoCyte Advanteon can be configured with, two, or three lasers and up to 21 fluorescence channels. It also has a 7.2 log dynamic range, and fully automated compensation features.

Jun 24, 2019

Cytek Biosciences Five-Laser Flow Cytometer

Cytek Biosciences launched the latest version of the Cytek Aurora advanced flow cytometry system, now available with five lasers to allow users to see more than 30 colors from a single sample. Among the features of the new instrument is that no optical filters need to be changed and any fluorochrome excited by the onboard lasers can be used. Sensitivity is improved as is resolution of dim and rare populations, Cytek added. 
Jun 19, 2019

Proscia's DermAI Digital Pathology Application

Proscia has launched DermAI, its first in a series of artificial intelligence applications for pathologists. DermAI, a module on the firm's Concentriq digital platform, uses deep learning to prescreen and classify skin biopsies, aiming to help reduce diagnostic errors and improve laboratory quality and efficiency, Proscia said. The artificial intelligence application reads and automatically classifies hundreds of variants of skin diseases into prediagnostic categories.

Jun 18, 2019

Biocept NGS Breast Panel

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations. 

Jun 17, 2019

Abbott Afinion HbA1c Dx Assay

Abbott announced that its Afinion HbA1c Dx assay is available for use on its Afinion 2 and Afinion AS100 analyzers. The Afinion HbA1c Dx assay is the first rapid point-of-care test cleared by the US Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the condition, Abbott said.

The test delivers accurate and precise HbA1c results in three minutes, enabling clinicians to diagnose patients and help them formulate individualized care plans during a single doctor's office visit, the firm said.

Jun 12, 2019

Patients Choice Laboratories UTI+ Test

Patients Choice Laboratories has launched the UTI+ molecular test for urinary tract infections. The Indianapolis-based company said the new test is part of its goal to be a full-service lab. It added that its gene- and molecular-based technologies provides uropathogenic and antibiotic resistance testing results within six hours after specimen receipt compared to up to three days with urinalysis by culturing. 

Jun 04, 2019

Illumina VeriSeq NIPT Solution v2

Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version expands the range of chromosomal and sub-chromosomal conditions associated with birth defects that laboratories can screen for. The assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. It is available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.

May 28, 2019

Bio-Rad Laboratories D-100 Hemoglobin Testing System

Bio-Rad Laboratories has launched the D-100 Hemoglobin Testing System for total laboratory automation. The company said it is connecting the sytem to track systems for optimized HbA1c workflow. The D-100 Hemoglobin Testing System now has point-in-space pipetting capability allowing integration with total lab automation systems for direct aspiration of samples as they move along the track. Bio-Rad noted it can connect with Inpeco FlexLab automation systems. 

May 28, 2019

Roche Ventana ROS1 Rabbit Monoclonal Primary Antibody

Roche launched the Ventana ROS1 rabbit monoclonal primary antibody, which the company said is the first and only in vitro diagnostic ROS1 immunhistochemistry assay. The test detects the presence of ROS1 protein in tisuue and may be used to identify ROS1-positive cancer in patients. College of American Pathologists and National Comprehensive Cancer Network guideliness recommend ROS1 testing for confirmed lung adenomcarcinoma cases, Roche noted. The test is a US class I/CE IVD device and can be used with Roche's BenchMark series of automated staining instruments. 

May 17, 2019

BioReference Laboratories Aerobic Vaginitis Testing

BioReference Laboratories and its specialty women’s health division, GenPath, launched new testing for aerobic vaginitis, a vaginal infection caused by the overgrowth of aerobic bacteria that triggers an inflammatory response.

Aerobic vaginitis occurs with bacterial vaginosis in 36.9 percent of vaginal discomfort cases, but they are separate infections.

While similar, they require different treatment regimes, BioReference said. If untreated, complications of aerobic vaginitis include an increased risk for contracting sexually transmitted infections, pelvic inflammatory disease, infertility, premature labor, preterm delivery, and premature rupture of membranes.

May 16, 2019

Siemens Healthineers Hemoglobin A1c Test on Atellica Solution

Siemens Healthineers announced the global availability of its new Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians in diagnosing and monitoring diabetes.

The firm said that demands will continue to grow on laboratories for screening and monitoring as the diabetic population continues to expand. It noted that instruments with higher throughput capabilities offer laboratories the ability to run a greater volume of tests and produce patient results more quickly, and laboratories are seeking HbA1c assays that can be integrated onto chemistry testing platforms. The Atellica CH Enzymatic Hemoglobin A1c Assay offers these capabilities, Siemens said.

May 14, 2019

Primerdesign Genesig q32

Primerdesign, the molecular business of Novacyt, has launched a next-generation molecular testing instrument called Genesig q32. The new qPCR instrument is larger than the firm's Genesig q16 instrument and provides customers with a faster, higher throughput solution for using Novacyt's genesig real-time PCR kits. The q32 provides test results within 60 minutes using Genesig kits, processing up to 32 patient samples in tube or strip format with fluorescence detection technologies.

May 02, 2019

Proscia Concentriq

Proscia has released the latest update of its Concentriq digital pathology platform. Improvements include a new performance analytics module in addition to a new suite of automation features. The features include a metrics dashboard, intelligence workload balancing, automated trigger-based notifications and alerts, and automted case actions. 

May 01, 2019

Arc Bio Galileo Pathogen Solution, GPS-Transplant

Arc Bio has launched the Galileo Pathogen Solution product line and first product, GPS-Transplant, a research-use-only next-generation sequencing test to aid in monitoring post-transplant patients for viral infections. GPS-Transplant detects the most common viral infections among transplant patients, including cytomegalovirus, Epstein–Barr virus, BK virus, and human adenovirus. The test also detects different variances and genotypes of the viruses, as well as more rare infections. GPS-Transplant also offers the ability to detect antiviral resistance mutations, and performs simultaneous quantitative detection of more than 350 viral strains. It is a sample-to-report solution built around the Illumina NGS platform that consists of reagents, built-in assay controls, and Galileo Analytics, a cloud-based proprietary software that provides quick and reliable results, an intuitive user interface, and detailed, actionable reports. The analytics software leverages Arc Bio's curated pathogen database called ArcIve, and also incorporates AMR resistance prediction technology which Arc Bio launched last year.